Navigation Links
Peramivir protects mice from lethal H5N1 infection

The antiviral drug peramivir might offer humans significant protection during a pandemic of the avian influenza virus H5N1, according to results of mouse studies conducted by investigators at St. Jude Children's Research Hospital.

Peramivir, an antiviral drug, blocks the ability of influenza viruses to use an enzyme called neuraminidase, thus preventing the release of new virus particles and their spread from one infected cell to another.

The St. Jude team studied different approaches to treating infected mice according to duration of administration (one day versus eight days); route of administration of peramivir (intramuscular injections alone versus intramuscular injections followed by oral administration) and frequency of administration on the first day of treatment (once versus twice). In all cases, the investigators administered peramivir to mice one hour after nasally administering a lethal Vietnam strain of H5N1 influenza virus.

The researchers reported 100 percent survival among 10 infected mice given intramuscular injections of peramivir daily for eight days. The drug also inhibited replication of the deadly strain of H5N1 virus in the lung, brain and spleen. The key to the high survival rate was treating the infected mice within 24 hours after infection with H5N1 and continuing the treatment for eight days. In contrast, a single intramuscular injection resulted in a 40 percent survival rate, while two intramuscular injections increased the rate to 60 percent. The single intramuscular injection did not completely inhibit H5N1 virus replication in the lungs and spleen, but did decrease the spread of virus to the brain.

"Peramivir should be given as soon as H5N1 infection is suspected, since onset of symptoms in infected humans can be delayed," said David A. Boltz, Ph.D., a postdoctoral fellow in the laboratory of Robert G. Webster in the Infectious Diseases department at St. Jude. "The drug could also be given as a p
'"/>

Source:St. Jude Children's Research Hospital


Page: 1 2

Related biology news :

1. Bound for destruction: Ubiquitination protects against improper Notch signaling
2. Experiments provide proof of how traveling in groups protects insects
3. Experiments provide proof of how traveling in groups protects insects
4. Substance protects resilient staph bacteria
5. Molecule that usually protects infection-fighting cells may cause plaque deposits inside arteries
6. NSAID drug protects against intestinal tumors in mice, despite poor diet and gene losses
7. Mutation in clams protects against paralytic shellfish poisoning but raises human health risk
8. Excess liver gene protects against high-fat diet
9. New vaccine protects more effectively against tuberculosis
10. New type of rejection blocker protects kidneys after transplant
11. How cell suicide protects plants from infection
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Peramivir protects mice from lethal infection

(Date:8/12/2015)... Minn. , Aug. 12, 2015   MedNet ... supports the entire spectrum of clinical research, is proud ... , the company,s comprehensive SaaS-based eClinical technology platform, has ... during the first two quarters of 2015.   Q2 ... second largest quarters measured by contract value sold in ...
(Date:8/10/2015)... , August 10, 2015 ... Eye Tracking Technology for more than two decades, announces ... for integration into all consumer display formats. The SMI ... integration of eye tracking into consumer tablets, laptops, desktop ... smart glasses. Omnivision,s leading sensor technology contributes to the ...
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... , Oct. 21, 2013   Arcturus Therapeutics, Inc. , an industry ... today announced it has secured $5 million in a Series A ... Canada , Japan and ... http://photos.prnewswire.com/prnh/20130531/MM24393LOGO ) The Series A funding, which comprised ...
... MA In a biological quirk that promises to ... potentially treating Fragile X syndrome, scientists at the University ... out a gene important for messenger RNA (mRNA) translation ... in a mouse model of a prevalent human neurological ...
... Jude Children,s Research Hospital scientists has linked an inherited ... developing a pediatric acute lymphoblastic leukemia (ALL) subtype that ... today in the online edition of the scientific journal ... found in the GATA3 gene. Researchers reported the high-risk ...
Cached Biology News:Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014 2Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014 32 genetic wrongs make a biochemical right 22 genetic wrongs make a biochemical right 32 genetic wrongs make a biochemical right 4Inherited gene variation tied to high-risk pediatric leukemia and greater risk of relapse 2Inherited gene variation tied to high-risk pediatric leukemia and greater risk of relapse 3
(Date:9/3/2015)... , Sept. 3, 2015  Guardant Health®, the ... abstracts highlighting the performance and clinical utility of ... for oral and poster presentations at the International ... World Conference on Lung Cancer. These abstracts were ... of California, Davis; the University of Chicago; Sarah ...
(Date:9/3/2015)... , September 3, 2015 According ... by System (LC (HPLC, UHPLC, Flash), GC, Other Components ... Syringe Filters, Vials) - Analysis & Global Forecasts to ... expected to reach around 9.223 Billion by 2020 from ... 5.5%. Browse 141 tables and 36 figures ...
(Date:9/2/2015)... , Sept. 2, 2015 Axovant Sciences Ltd. ... treatment of dementia, today announced upcoming presentations at three investor ... at the Baird 2015 Healthcare Conference in New ... , Thursday, September 10 at 2:00 PM at the BioCentury ... the Millennium Broadway Hotel & Conference Center , Thursday, ...
(Date:9/2/2015)... Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report ... to their offering. This report ... technologies and applications. The report starts with a ... of markets. Technologies include array comparative genomic hybridization ...
Breaking Biology Technology:Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 2Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 3Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 4Chromatography Instruments Market Worth $ 9.223 Billion by 2020 2Chromatography Instruments Market Worth $ 9.223 Billion by 2020 3Chromatography Instruments Market Worth $ 9.223 Billion by 2020 4Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2
... Forest Laboratories, Inc.,(NYSE: FRX ), an ... its Fiscal 2009 Second Quarter financial results,before the ... 2008. Later that,day, at 10:00 AM EDT, Forest ... President and Chief Operating Officer and Frank Perier, ...
... (OTC,Bulletin Board: SCIE), a San Diego-based medical device ... WavSTAT(R) Optical Biopsy,System to the University of Southern ... Biopsy System as an adjunctive tool to improve,clinical ... esophagus.,This marks the final phase of a study ...
... October 1 Excalibur, the international,investment house specialising ... be achieved in the UK biotech sector,despite the ... Professor Sir Christopher Evans and a development,of Merlin ... York Pharma plc, the specialist dermatology company, to ...
Cached Biology Technology:Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings 2University of Southern California Receives Cancer Diagnosis System for Detecting Esophageal Dysplasia 2University of Southern California Receives Cancer Diagnosis System for Detecting Esophageal Dysplasia 3University of Southern California Receives Cancer Diagnosis System for Detecting Esophageal Dysplasia 4Excalibur - 'Transforming' Biotech Deals can Still be Achieved 2
Parathyroid Hormone Receptor 2 [PTHR2]...
... a member of the caudal-related homeobox family, ... both proliferation and differentiation in intestinal epithelial ... triggering cells towards the phenotype of differentiated ... maintenance of the phenotype. Clone CDX2-88 reacts ...
... a G1 cyclin required for G1-phase progression ... proto-oncogene. cyclin D2 can phosphorylate pRB ... Reactivity: Human, Mouse, and Rat. ... particularly well suited for neutralization of cyclin ...
... Immunogen: Synthetic ... 22-37 SGHKSEEKREKMKRTL Antigen Family: ... signalling; Antigen Subfamily: ... signalling Recommended Storage: ...
Biology Products: